Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVRd regimen for newly diagnosed multiple myeloma with extramedullary disease
ChiCTR2600124493Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone in multiple myeloma (MM) and extramedullary disease (EMD), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Objective Response Rate, Duration of Response and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
mitoxantrone
03
Conditions
multiple myeloma (MM)extramedullary disease (EMD)
Beyond the preview
Go deeper on ChiCTR2600124493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124493.